Summary
In this episode of the Drive podcast, neurologist Kellyanne Paterson discusses neurodegenerative diseases with host Peter Attia. Paterson explains the different types of neurodegenerative diseases, including Alzheimer's, vascular dementia, Lewy Body dementia, and Parkinson's disease, and how they affect different parts of the brain and associated symptoms. The conversation also touches on the overlap between vascular dementia and Alzheimer's dementia and the potential role of insulin resistance in neurodegeneration.
The discussion focuses on the triggers and genetic factors associated with Parkinson's disease and the importance of tracking sleep in patients with Parkinson's Disease, particularly in relation to their REM sleep. The lack of a biomarker for Parkinson's Disease makes prevention difficult, but the speaker suggests that understanding the underlying mechanisms of neurodegenerative diseases can help with risk assessment and early intervention.
The conversation also covers the use of PET scans to identify amyloid deposition in the brain, but notes that this doesn't necessarily mean the person is on the path to Alzheimer's disease. The discussion revolves around the use of Tau scans in detecting Alzheimer's disease and the progression of cognitive impairment. The context discusses the different aspects of cognitive testing, including visual spatial processing, episodic memory, executive function, and verbal learning.
The speakers also discuss the importance of maintaining good oral health for overall health and how poor oral health can increase the risk of Alzheimer's and other neurodegenerative diseases. Additionally, the role of genetics, specifically the apoe4 gene, on the risk of Alzheimer's and other neurodegenerative diseases is explored.
The conversation concludes with a discussion on the importance of exercise in improving brain health and the need for better approaches to managing neurodegenerative diseases. The speakers believe that a better understanding of genetics and family history, along with cognitive and movement assessments, can lead to targeted preventative strategies for neurodegenerative conditions.
